This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis | MicrobiomeTrials
← Back to trials NCT07895615
Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-10Est. Completion: 2028-01
Enrollment target: 160 participantsLocations Hangzhou First People's Hospital, Hangzhou, Zhejiang, China Other microbiome trials you might be interested in Atopic Dermatitis
This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic…
Los Angeles, United States Est. completion Mar 1, 2033
Hyper IgE Syndrome From STAT3 Mutation Job s Syndrome HIES Lupus Atopic Dermatitis
Background:
Autosomal dominant hyper-IgE syndrome (HIES), also called Job syndrome, is a genetic disorder that affects …
Bethesda, United States Est. completion May 1, 2030